「個人化」化學治療（調整劑量或延長給藥時間）

Corsetti MT, Salvi F, Perticone S, Baraldi A, De Paoli L, Gatto S, Pietrasanta D, Pini M, Primon V, Zallio F, Tonso A, Alvaro MG, Ciravegna G, Levis A.

出處‎: Leuk Res 2011;35(8):991-7.

檢索‎: PubMed 21474179

DOI碼‎: 10.1016/j.leukres.2011.02.021

https://www.ncbi.nlm.nih.gov/pubmed/21474179 （開啟新視窗）

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. （開啟新視窗）

Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR.

出處‎: Br J Haematol 2014;165(4):497-503.

檢索‎: PubMed 24528179

DOI碼‎: 10.1111/bjh.12775

https://www.ncbi.nlm.nih.gov/pubmed/24528179 （開啟新視窗）

Low-dose cytosine arabinoside as an alternative treatment for acute leukemia in Jehovah's Witnesses. （開啟新視窗）

Dainer PM, Knupp CL, Sartiano GP.

出處‎: Am J Hematol 1992;40(2):156-7.

檢索‎: PubMed 1585917

https://www.ncbi.nlm.nih.gov/pubmed/1585917 （開啟新視窗）

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. （開啟新視窗）

Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A.

出處‎: Lancet Oncol 2013;14(6):525-33.

檢索‎: PubMed 23578722

DOI碼‎: 10.1016/S1470-2045(13)70122-0

https://www.ncbi.nlm.nih.gov/pubmed/23578722 （開啟新視窗）

Azacitidine and venetoclax in previously untreated acute myeloid leukemia. （開啟新視窗）

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW

出處‎: N Engl J Med 2020;383(7):617-29.

檢索‎: PubMed 32786187

DOI碼‎: 10.1056/NEJMoa2012971

https://www.ncbi.nlm.nih.gov/pubmed/32786187 （開啟新視窗）

Treatment of acute leukaemia in adult Jehovah's Witnesses. （開啟新視窗）

El Chaer F, Ballen KK

出處‎: Br J Haematol 2020;190(5):696-707.

檢索‎: PubMed 31693175

DOI碼‎: 10.1111/bjh.16284

https://www.ncbi.nlm.nih.gov/pubmed/31693175 （開啟新視窗）

Minimally-myelosuppressive asparaginase-containing induction regimen for treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS acute myeloid leukemia. （開啟新視窗）

Emadi A, Bade NA, Stevenson B, Singh Z.

出處‎: Pharmaceuticals (Basel) 2016;9(1):E12.

檢索‎: PubMed 27064021

DOI碼‎: 10.3390/ph9010012

https://www.ncbi.nlm.nih.gov/pubmed/27064021 （開啟新視窗）

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. （開啟新視窗）

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T.

出處‎: J Clin Oncol 2009;27(28):4733-40.

檢索‎: PubMed 19720927

DOI碼‎: 10.1200/JCO.2008.19.8721

https://www.ncbi.nlm.nih.gov/pubmed/19720927 （開啟新視窗）

Successful treatment of a Jehovah's Witness with acute promyelocytic leukemia. （開啟新視窗）

Fujita H, Maruta A, Koharazawa H, Hattori M, Tomit N, Kodama F, Mohri H, Okubo T.

出處‎: Int J Hematol 1997;65(4):415-6.

檢索‎: PubMed 9195782

https://www.ncbi.nlm.nih.gov/pubmed/9195782 （開啟新視窗）

Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah's Witness with acute monocytic leukemia. （開啟新視窗）

Garelius H, Grund S, Stockelberg D.

出處‎: Clin Case Rep 2015;3(5):287-90.

檢索‎: PubMed 25984306

https://www.ncbi.nlm.nih.gov/pubmed/25984306 （開啟新視窗）

Immediate or delayed therapy with 2-CdA for hairy cell leukemia in Jehova's Witness? （開啟新視窗）

Juliusson G.

出處‎: Am J Hematol 1996;53(1):49.

檢索‎: PubMed 8813099

DOI碼‎: 10.1002/(SICI)1096-8652(199609)53:1<49::AID-AJH12>3.0.CO;2-Z

https://www.ncbi.nlm.nih.gov/pubmed/8813099 （開啟新視窗）

Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. （開啟新視窗）

Laszlo D, Agazzi A, Goldhirsch A, Cinieri S, Bertolini F, Rabascio C, Pruneri G, Calabrese L, Cocquio A, Martinelli G.

出處‎: Eur J Haematol 2004;72(4):264-7.

檢索‎: PubMed 15089764

DOI碼‎: 10.1111/j.0902-4441.2003.00211.x

https://www.ncbi.nlm.nih.gov/pubmed/15089764 （開啟新視窗）

Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah's Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin. （開啟新視窗）

Lin CP, Huang MJ, Liu HJ, Chang IY, Tsai CH.

出處‎: Am J Hematol 1996;51(3):251-2.

檢索‎: PubMed 8619417

DOI碼‎: 10.1002/(SICI)1096-8652(199603)51:3<251::AID-AJH20>3.0.CO;2-I

https://www.ncbi.nlm.nih.gov/pubmed/8619417 （開啟新視窗）

Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. （開啟新視窗）

Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, Huang J, Jin J.

出處‎: Hematol Oncol 2014;32(1):40-6.

檢索‎: PubMed 23963734

DOI碼‎: 10.1002/hon.2076

https://www.ncbi.nlm.nih.gov/pubmed/23963734 （開啟新視窗）

Cytarabine dose for acute myeloid leukemia. （開啟新視窗）

Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group.

出處‎: N Engl J Med 2011;364(11):1027-36.

檢索‎: PubMed 21410371

DOI碼‎: 10.1056/NEJMoa1010222

https://www.ncbi.nlm.nih.gov/pubmed/21410371 （開啟新視窗）

Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. （開啟新視窗）

Mazza P, Prudenzano A, Amurri B, Palazzo G, Pisapia G, Stani L, Pricolo G.

出處‎: Bone Marrow Transplant 2003;32(4):433-6.

檢索‎: PubMed 12900781

DOI碼‎: 10.1038/sj.bmt.1704179

https://www.ncbi.nlm.nih.gov/pubmed/12900781 （開啟新視窗）

Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. （開啟新視窗）

Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh SP, Daigle SR, Hui J, Pandya SS, Gianolio DA, de Botton S, Döhner H

出處‎: N Engl J Med. 2022;386(16):1519-31.

檢索‎: PubMed 35443108

DOI碼‎: 10.1056/NEJMoa2117344

https://pubmed.ncbi.nlm.nih.gov/35443108/ （開啟新視窗）

Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. （開啟新視窗）

Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, Fowler JM, Copeland LJ, Salani R.

出處‎: Gynecol Oncol 2012;124(2):221-4.

檢索‎: PubMed 22055764

DOI碼‎: 10.1016/j.ygyno.2011.10.003

https://www.ncbi.nlm.nih.gov/pubmed/22055764 （開啟新視窗）

The treatment of acute lymphoblastic leukemia in Jehovah's Witnesses and patients who cannot accept blood products. （開啟新視窗）

Nguyen N, Madarang E, Alencar A, Watts J, Bradley T

出處‎: Leuk Res Rep. 2022 25;18:100355.

檢索‎: PubMed 36338830

DOI碼‎: 10.1016/j.lrr.2022.100355

https://pubmed.ncbi.nlm.nih.gov/36338830/ （開啟新視窗）

Developing a blood conservation care plan for Jehovah's Witness patients with malignant disease. （開啟新視窗）

Norfolk DR, Wade P, Carter R.

出處‎: Presented at the British Society for Haematology 47th Annual Scientific Meeting, Bournemouth [UK] April 2007.

https://www.transfusionguidelines.org/document-library/documents/developing-a-blood-conservation-care-plan-for-jehovah-s-witness-patients-with-malignant-disease/download-file/bbt-JW-Care-Plan-Malignant-Disease-2012.pdf （開啟新視窗）

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. （開啟新視窗）

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

出處‎: Leuk Lymphoma. 2019;60(9):2324-7.

檢索‎: PubMed 30773115

DOI碼‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 （開啟新視窗）

Hematopoietic growth factors: personalization of risks and benefits. （開啟新視窗）

Puhalla S, Bhattacharya S, Davidson NE.

出處‎: Mol Oncol 2012;6(2):237-41.

檢索‎: PubMed 22497867

DOI碼‎: 10.1016/j.molonc.2012.03.001

https://www.ncbi.nlm.nih.gov/pubmed/22497867 （開啟新視窗）

Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. （開啟新視窗）

Riedell PA, Wu M, Collins JM, Gideon JM, Jakubowiak AJ, Kline JP, Kosuri S, Liu H, Smith SM, Bishop MR

出處‎: Leuk Lymphoma 2021;62(6):1497-501.

檢索‎: PubMed 33535838

DOI碼‎: 10.1080/10428194.2021.1876868

https://www.ncbi.nlm.nih.gov/pubmed/33535838 （開啟新視窗）

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. （開啟新視窗）

Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM

出處‎: Blood 2020;135(7):463-71.

檢索‎: PubMed 31841594

DOI碼‎: 10.1182/blood.2019002140

https://www.ncbi.nlm.nih.gov/pubmed/31841594 （開啟新視窗）

Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience. （開啟新視窗）

Ruiz-Argüelles GJ, Morales-Toquero A, López-Martínez B, Tarín-Arzaga LD, Manzano C.

出處‎: Bone Marrow Transplant 2005;36(8):715-20.

檢索‎: PubMed 16113672

DOI碼‎: 10.1038/sj.bmt.1705126

https://www.ncbi.nlm.nih.gov/pubmed/16113672 （開啟新視窗）

A Mexican way to cope with stem cell grafting. （開啟新視窗）

Ruiz-Delgado GJ, Ruiz-Argüelles GJ.

出處‎: Hematology 2012;17 Suppl 1:S195-7.

檢索‎: PubMed 22507819

DOI碼‎: 10.1179/102453312X13336169157130

https://www.ncbi.nlm.nih.gov/pubmed/22507819 （開啟新視窗）

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. （開啟新視窗）

Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F.

出處‎: Blood 2009;113(9):1875-91.

檢索‎: PubMed 18812465

DOI碼‎: 10.1182/blood-2008-04-150250

https://www.ncbi.nlm.nih.gov/pubmed/18812465 （開啟新視窗）

SCT in Jehovah's Witnesses: the bloodless transplant. （開啟新視窗）

Sloan JM, Ballen K.

出處‎: Bone Marrow Transplant 2008;41(10):837-44.

檢索‎: PubMed 18246110

DOI碼‎: 10.1038/bmt.2008.5

https://www.ncbi.nlm.nih.gov/pubmed/18246110 （開啟新視窗）

Treatment of acute myelogenous leukemia with outpatient azacitidine. （開啟新視窗）

Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB, Kennedy M, Gryn JF, Faroun Y, Lister J.

出處‎: Cancer 2006;107(8):1839-43.

檢索‎: PubMed 16967444

DOI碼‎: 10.1002/cncr.22204

https://www.ncbi.nlm.nih.gov/pubmed/16967444 （開啟新視窗）

Isolated limb perfusion for an irresectable melanoma recurrence in a Jehovah's Witness. （開啟新視窗）

van Akkooi AC, Golab-Schwarz HD, Eggermont AM, van Geel AN.

出處‎: Eur J Cardiothorac Surg 2006;30(2):408-10.

檢索‎: PubMed 16829108

DOI碼‎: 10.1016/j.ejcts.2006.04.020

https://www.ncbi.nlm.nih.gov/pubmed/16829108 （開啟新視窗）

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. （開啟新視窗）

Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA.

出處‎: Onco Targets Ther 2013;7:13-21.

檢索‎: PubMed 24368888

DOI碼‎: 10.2147/OTT.S53348

https://www.ncbi.nlm.nih.gov/pubmed/24368888 （開啟新視窗）

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. （開啟新視窗）

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS.

出處‎: J Clin Oncol 2007;25(30):4722-9.

檢索‎: PubMed 17947719

DOI碼‎: 10.1200/JCO.2007.12.2440

https://www.ncbi.nlm.nih.gov/pubmed/17947719 （開啟新視窗）

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. （開啟新視窗）

Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P

出處‎: Blood 2020;135(24):2137-45.

檢索‎: PubMed 32219442

DOI碼‎: 10.1182/blood.2020004856

https://www.ncbi.nlm.nih.gov/pubmed/32219442 （開啟新視窗）